Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionBenzinga • 09/08/26
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock DownZacks Investment Research • 09/07/26
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study GoalZacks Investment Research • 09/07/26
A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 studyWSJ • 09/04/26
Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental researchWSJ • 09/03/26
This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One24/7 Wall Street • 09/03/26
Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS StudiesZacks Investment Research • 09/02/26
Panmure Liberum says OxfordBiomedica share fall overdone after Novartis and BMS pause trialsProactive Investors • 09/02/26